Latest News & Features
Refine Search
Asia-Pacific
Criminal gangs in Australia are branching away from traditional forms of counterfeiting and are targeting pharmaceuticals, an Australian customs official has revealed. 9 October 2014
Genetics
A US appeals court has heard oral arguments in a case between Myriad Genetics and a generics company it wants to prevent from marketing its own test for BRCA gene mutations that can lead to breast cancer. 8 October 2014
Biotechnology
A patent belonging to Pluristem Therapeutics covering a treatment for ischemia has been upheld by the European Patent Office following opposition proceedings, the company has announced. 8 October 2014
Americas
US life sciences analysis company Sequenom has agreed a multi-million dollar deal to buy patents related to prenatal testing from UK-based technology transfer company Isis Innovation. 7 October 2014
Big Pharma
Drug business Teva invalidated two patents held by Leo Pharma today and will seek to launch a generic version of one of the company’s skin condition treatments. 6 October 2014
Big Pharma
Pharmaceutical company CleveXel Pharma has agreed a deal with a technology transfer company to licence two patents related to the treatment of bone marrow cancer. 6 October 2014
Americas
Law firm Blank Rome has expanded its litigation department with the appointment of life science specialist and partner Gary Ruckelshaus. 3 October 2014
Americas
US-based specialty drugs company Supernus Pharmaceuticals has sued generics maker Actavis, accusing it of infringing three patents related to an antiepileptic drug. 3 October 2014
Americas
Biopharmaceutical company Opexa Therapeutics has expanded its IP portfolio to include nearly 100 validated patents worldwide, the company has said. 1 October 2014
Americas
Earlier this month, the first LSIPR roundtable discussion took place in a London hotel, chaired by managing editor Martin Essex, with six invited experts and deputy editor
Ed Conlon taking part. We’ll be publishing a special report on the event but, to whet your appetite, here’s how the discussion began—with a lively debate on the USPTO’s guidelines on patent-eligible subject matter in the wake of the Myriad and Mayo court decisions. 30 September 2014